Daewon Pharmaceutical Co., Ltd.

South Korea, Seoul

Report a bug?

Claim ownership and edit

Description

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Industries

Pharmaceutical and Medicine Manufacturing; Chemical Manufacturing; Manufacturing

SIC

Pharmaceutical Preparations; Chemicals and Allied Products; Manufacturing

Address:

386 Cheonho-daero

Seongdong-gu Seoul

Seoul

04808 Republic Of Korea

Website:

www.daewonpharm.com/main/index.jsp

Revenue

KRX - Delayed Quote - KRW

003220.KS

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 03/21/2026

Market Cap: 223.34 B

Enterprise Value: 368.54 B

Trailing P/E: 29.21

Forward P/E: 11.62

PEG Ratio (5yr expected): N/A

Price/Sales (ttm): 0.38

Price/Book (mrq): 0.87

Enterprise Value/Revenue: 0.62

Enterprise Value/EBITDA: 18.34

Financial Highlights

Profitability and Income Statement

Profit Margin: -2.72%

Return on Assets (ttm): -0.04%

Return on Equity (ttm): -6.76%

Revenue (ttm): 590.70 B

Net Income Avi to Common (ttm): -14.81 B

Diluted EPS (ttm): N/A

Balance Sheet and Cash Flow

Total Cash (mrq): 68.22 B

Total Debt/Equity (mrq): 80.88%

Levered Free Cash Flow (ttm): -11.76 B

Company is likely to buy

Company is likely to sell

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.